Renal denervation is a catheter-based minimally invasive procedure. It is a therapy carried out by radiofrequency or ultrasound ablation for uncontrolled hypertension. Renal denervation is performed through endovascular catheter-based procedure to treat hypertension, which is beyond medication control. The procedure consists of a catheter that emits radiofrequency energy across multiple electrodes. Radiofrequency pulse is applied to the renal artery, which causes the wall of artery to ablate, reducing the nerve activity, thereby reducing blood pressure. The progress of catheter-based interventional therapies has yielded impressive results in certifying enhanced blood pressure control in patients with complaints of uncontrolled hypertension, vascular, and cardiovascular diseases.
To understand Research Methodology, please click: https://www.coherentmarketinsights.com/insight/request-sample/798
Effective treatment through minimally invasive catheter-based endovascular procedure to drive market growth
According to the International Journal of Hypertension in 2013, atrial hypertension affects around 24.8% of the global population, posing morbidity and mortality. Rising prevalence of hypertension with inefficient anti-hypertensive medicines, lasting effect of renal denervation, and fast development of renal denervation devices are expected to drive the growth of renal denervation devices market. The market is expected to grow drastically with the FDA approval of Symplicity HTN-4 renal denervation device, owing to its targeted radiofrequency energy delivery, thereby minimizing the potential threat to surrounding tissues. The market for renal denervation devices and associated processes is also driven by advantages such as higher safety, reduced treatment time, permanent effect, and rising incidence of uncontrolled & treatment-resistant hypertension.
Europe is expected to account for maximum market share, owing to the significant R&D investments by market participants operating in the region
Regional segmentation of the global renal denervation devices market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The renal denervation devices market in Europe is considered to be the biggest, owing to the increasing number of drug-resistant hypertension cases and technological advances for manufacturing efficient devices. According to the American Heart Association estimates in 2013, around 33% (nearly 70 million people) of the U.S. adult population suffer from high blood pressure. The rising occurrence of uncontrolled hypertension and increasing FDA approvals for drugs are expected to be the major factors driving market growth in North America in the forecast period.
To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/798
Innovation in products is expected to generate higher revenue for the manufacturers
Key players operating in the renal denervation devices market include Medtronic Plc., St. Jude Medical, ReCor Medical Inc., Boston Scientific Corporation, and Cardiosonic Ltd. The market participants are engaged in research and development for introducing innovative and differentiated products in the market. For instance, Symplicity HTN-2 developed by Medtronic and EnligHTN TN developed by St. Jude Medical are proven to be effective and therefore are largely adopted by patients. Other prominent vendors include Ablative Solutions Inc., Mercator MedSystems Inc., Jude Medical Inc., and Terumo Medical Corporation, among others.